• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Verastem Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    12/19/25 5:21:51 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VSTM alert in real time by email
    false 0001526119 0001526119 2025-12-15 2025-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K 

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): December 15, 2025

     

    Verastem, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-35403   27-3269467
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    117 Kendrick Street, Suite 500, Needham, MA   02494
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (781) 292-4200

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange on which registered
    Common stock, $0.0001 par value per share   VSTM   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    Departure of Chief Operating Officer

     

    As previously disclosed on December 15, 2025, as of December 19, 2025, Matthew Ros separated from Verastem, Inc. (the "Company") as its Chief Operating Officer.

     

    In connection with his separation, on December 19, 2025, the Company entered into a Separation Agreement (the “Separation Agreement”) with Mr. Ros. Under the Separation Agreement, Mr. Ros will receive severance benefits consistent with his employment agreement with the Company, dated January 14, 2025. These benefits include (i) nine months of base salary continuation, (ii) if Mr. Ros exercises his right to continue participation in the Company’s health and dental plans under the federal law known as COBRA, a monthly cash amount equal to the full premium cost of that participation for nine months (or, if earlier, until the time when Mr. Ros becomes eligible to enroll in the health or dental plan of a new employer) and (iii) a pro-rated bonus payment for the portion of the year during which Mr. Ros was employed by the Company prior to the separation, with the actual amount of any bonus determined by actual performance of the Company.

     

    The Separation Agreement includes customary provisions regarding release of claims, non-disparagement, cooperation and return of Company property.

     

    The foregoing summary of the Separation Agreement is qualified in its entirety by the copy of the Separation Agreement filed as Exhibit 10.1 hereto and incorporated herein by this reference.

     

    Item 7.01 Regulation FD Disclosure

     

    On December 15, 2025, the Company issued a press release announcing, among other developments, Mr. Ros’s departure.

     

    A copy of this press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.

     

    Item 9.01. Financial Statements and Exhibits

     

    Exhibit No.   Description
    10.1   Separation Agreement dated December 19, 2025 by and between Verastem, Inc. and Matthew Ros
    99.1   Press Release, dated December 15, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      VERASTEM, INC.
         
    Dated: December 19, 2025 By: /s/ Daniel W. Paterson
        Daniel W. Paterson
        President and Chief Executive Officer

     

     

     

    Get the next $VSTM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VSTM

    DatePrice TargetRatingAnalyst
    10/16/2025Overweight
    Cantor Fitzgerald
    4/10/2025$15.00Buy
    Jefferies
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    9/30/2024$13.00Buy
    Guggenheim
    11/21/2023$27.00Buy
    BTIG Research
    9/27/2023$21.00Buy
    B. Riley Securities
    6/15/2023$24.00 → $36.00Neutral → Buy
    Mizuho
    More analyst ratings

    $VSTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida. A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to develo

    11/25/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced underwritten public offering of 8,543,794 shares of its common stock at an offering price to the public of $7.25 per share, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,870,000 shares of its common stock at an offering price to the public of $7.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gro

    11/14/25 12:41:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    SEC Filings

    View All

    $VSTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $VSTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Verastem Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    12/19/25 5:21:51 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Verastem Inc.

    144 - Verastem, Inc. (0001526119) (Subject)

    11/21/25 4:20:44 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    11/17/25 7:30:39 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Stuglik Brian M sold $5,411 worth of shares (592 units at $9.14), decreasing direct ownership by 0.58% to 101,147 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    12/18/25 4:47:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Paterson Dan sold $3,592 worth of shares (393 units at $9.14), decreasing direct ownership by 0.10% to 410,425 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    12/18/25 4:46:13 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gagnon Robert E. sold $2,587 worth of shares (283 units at $9.14), decreasing direct ownership by 0.67% to 41,678 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    12/18/25 4:45:15 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Verastem

    Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight

    10/16/25 8:50:56 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Verastem with a new price target

    Jefferies initiated coverage of Verastem with a rating of Buy and set a new price target of $15.00

    4/10/25 12:44:18 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Verastem with a new price target

    H.C. Wainwright reiterated coverage of Verastem with a rating of Buy and set a new price target of $10.00 from $7.00 previously

    3/24/25 7:46:47 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/24/24 4:00:39 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Leadership Updates

    Live Leadership Updates

    View All

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market

    3/20/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

    New executive leadership supports the company's transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025. Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. "We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and th

    1/15/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Financials

    Live finance-specific insights

    View All

    Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

    Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported; no nausea, vomiting or diarrhea greater than Grade 1 were observed Enrollment initiated for VS-7375 in combination with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer Ended Q3 2025 with $137.7 million in cash and cash equivalents; with expected product revenue and exercise of cash warrants, Company cash runway would extend into the second half of 2026 Company to host a conference call and webcast today at 8:00 a.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical compa

    11/4/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv

    10/23/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

    Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors Ended Q2 2025 with $164.3 million in cash and cash equivalents; with product revenue and exercise of cash warrants, Company has expected cash runway into the second half of 2026 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for

    8/7/25 4:05:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:38:53 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verastem Inc.

    SC 13G - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:36:17 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care